Welcome to our dedicated page for Nervgen Pharma SEC filings (Ticker: NGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to NervGen Pharma Corp. (NGEN) regulatory filings and related disclosures, alongside AI-generated summaries that help explain their contents in clear language. While no SEC filings are listed in the current data, NervGen’s public statements outline the clinical and regulatory context in which future filings would be prepared.
NervGen describes itself as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, is a subcutaneously administered neuroreparative peptide evaluated in the Phase 1b/2a CONNECT SCI Study in individuals with chronic SCI, with ongoing enrollment in subacute SCI and preparation for a Phase 3 trial in chronic SCI.
According to the company, NVG-291 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of spinal cord injury. NervGen also references regulatory meetings with the FDA, including a Type C meeting and a planned End-of-Phase 2 meeting to align on the development and registration pathway for NVG-291.
As SEC filings such as annual reports (Form 10-K), quarterly reports (Form 10-Q) or current reports (Form 8-K) become available, this page can surface them with AI-powered highlights of key sections, such as clinical development updates for NVG-291 and NVG-300, risk factor discussions related to neuroreparative drug development, and disclosures around regulatory designations and trial status. AI summaries can assist readers in navigating lengthy documents by pointing to passages that discuss NervGen’s spinal cord injury focus, neurotraumatic and neurologic indications, and the company’s stated mission to enable nervous system repair.
NervGen Pharma Corp. has entered into a Sales Agreement with Leerink Partners LLC that allows the company to issue and sell up to US$50,000,000 of its common shares from time to time. These sales will be made as an at-the-market offering on Nasdaq or other U.S. trading venues, at prevailing market prices.
The shares are offered under NervGen’s existing Form F-10 shelf registration, which covers up to US$250,000,000 of various securities, and a corresponding Canadian short form base shelf prospectus. NervGen controls when and how many shares are sold via Placement Notices, can suspend or terminate offerings at any time, and is not obligated to sell any shares.
Leerink acts as selling agent on a commercially reasonable efforts basis, with cash settlement of net proceeds to NervGen on each trading day that shares are sold. The company agrees to use net proceeds as described in the “Use of Proceeds” sections of its U.S. and Canadian prospectuses.
NervGen Pharma Corp. completed an underwritten public Offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares at a combined public offering price of US$2.50 per share and warrant. This equity financing is expected to generate approximately US$60.0 million in gross proceeds before fees and expenses, excluding any cash that may come from future warrant exercises.
Each warrant carries an exercise price of US$3.68 per share, is immediately exercisable, and expires five years from issuance. NervGen plans to use the net proceeds, together with existing cash, to advance its NVG-291 program through clinical studies and for general corporate and working capital needs. Insider PFP Biosciences Holdings LLC participated in the Offering, increasing its holdings to 15,488,673 common shares (14.58% of outstanding) and 8,144,335 warrants, which include a 19.99% ownership cap on warrant exercise.
NervGen Pharma reports new independent, blinded biomechanical gait analyses from its Phase 1b/2a CONNECT SCI study showing a statistically significant treatment effect of NVG-291 versus placebo on a multivariate measure of gait quality in people with chronic tetraplegia.
The analyses, performed by AI movement specialist Newton Tech and independently verified by a computational biomedicine department, assessed coordination, mechanical effort and postural stability, which are described as hallmarks of genuine neural recovery rather than compensation. Participants were 1–10 years post–spinal cord injury, with a mean of 3.5 years.
NervGen states these results extend previously reported clinical improvements and support advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, which is planned to start in mid-2026 following an earlier End-of-Phase 2 FDA meeting and ongoing regulatory dialogue.
NervGen Pharma Corp. amended its amended and restated short form base shelf prospectus to increase the aggregate offering capacity from U.S.$150,000,000 to U.S.$250,000,000, permitting offers of Common Shares, Debt Securities, Subscription Receipts, Warrants and Units to be made from time to time during the 25-month shelf period. The prospectus states the securities may be offered by the Company or by selling securityholders, and that specific terms will be set forth in prospectus supplements. The prospectus also discloses corporate, clinical and financial context including recent Phase 1b/2a data for NVG-291, the Private Placement of 4,785,674 units for aggregate gross proceeds of U.S.$10,049,915, and cash and loss figures for the period ended September 30, 2025.
NervGen Pharma Corp. has priced an underwritten public offering of 24,000,000 common shares and accompanying warrants to purchase up to 24,000,000 common shares. The securities are priced at US$2.50 per common share and accompanying warrant, for expected gross proceeds of about US$60.0 million.
Each warrant has an exercise price of US$3.68 per common share, is immediately exercisable, and will expire five years from issuance. All securities are being sold by NervGen, which plans to use the net proceeds, along with existing cash, to advance its lead drug candidate NVG-291 through clinical studies and for general corporate and working capital needs.
NervGen Pharma reported first quarter 2026 results and highlighted progress toward its RESTORE registrational study of NVG-291 in chronic tetraplegia. The company achieved FDA alignment on RESTORE’s study parameters and is focusing on initiating the trial in mid-2026 while activating study sites and expanding senior leadership.
As of March 31, 2026, NervGen held $16.6 million in cash and investments. R&D expenses were $4.9 million, up from $3.1 million a year earlier, and G&A expenses were $2.7 million versus $2.9 million in 2025. Net loss narrowed to $1.7 million, driven mainly by a $5.7 million non-cash unrealized gain on a warrant derivative.
The company’s lead candidate NVG-291, a subcutaneous neuroreparative peptide targeting the CSPG-PTPσ pathway, has FDA Fast Track and EMA Orphan Drug designations for spinal cord injury. NervGen is also developing next-generation candidate NVG-300 and evaluating additional neurotraumatic and neurologic indications.
NervGen Pharma filed a Form 6-K with unaudited IFRS results for the three months ended March 31, 2026. The company reported a net loss of $1,675,549, or $0.02 basic loss per share, compared with a loss of $3,948,192 a year earlier, mainly due to a larger non‑cash gain on its warrant derivative.
Research and development expenses rose to $4,863,626 and general and administrative expenses were $2,667,952. Cash and cash equivalents were $16,559,056 with total assets of $20,765,547 and total liabilities of $15,223,975. Management states there is material uncertainty about the company’s ability to continue as a going concern, noting that existing cash is expected to fund operations only through the second quarter of 2026 and that additional financing is required to support planned Phase 3 trials of NVG‑291 and other programs.
NervGen Pharma Corp. appointed Keith Vendola, MD, MBA as Chief Financial Officer, effective immediately. Under his employment agreement, he will receive an annual base salary of $515,000 and be eligible for an annual cash bonus of up to 40% of salary, subject to Board discretion.
As part of his package, the Board granted Dr. Vendola options to purchase 812,002 common shares at an exercise price of $3.92 per share, vesting in three equal annual installments over three years and expiring ten years after grant. These options were issued under NervGen’s new 2026 Equity Incentive Plan.
At the recent annual meeting, shareholders approved an amendment to the Company’s Articles and adopted the 2026 Equity Incentive Plan, alongside amendments to the existing stock option plan and the routine re-appointment of KPMG as auditor and election of eight directors. The 6-K and key exhibits are incorporated by reference into NervGen’s Form F-10 shelf registration.
NervGen Pharma Corp. files its Annual Report on Form 40-F for the fiscal year ended December 31, 2025. The filing lists 79,649,257 Common Shares outstanding, incorporates an Annual Information Form, audited consolidated financial statements for 2025 and 2024, MD&A, and certifications via listed exhibits. The registry signature is dated March 31, 2026.